Sign In
Buy CODX
$5.17
-1.05 (-16.88%)
At Close: Jun 03, 2026
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
06:15pm, Thursday, 14'th Aug 2025
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.
Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results
04:01pm, Thursday, 14'th Aug 2025
SALT LAKE CITY , Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast
09:30am, Thursday, 31'st Jul 2025
SALT LAKE CITY , July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025
09:30am, Tuesday, 15'th Jul 2025
SALT LAKE CITY , July 15, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development
Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
09:30am, Wednesday, 14'th May 2025
Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the
Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript
09:59pm, Thursday, 08'th May 2025
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Br
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Misses Revenue Estimates
08:10pm, Thursday, 08'th May 2025
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.
Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results
04:01pm, Thursday, 08'th May 2025
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests
Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast
07:30am, Tuesday, 29'th Apr 2025
SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic te
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy
01:05pm, Wednesday, 02'nd Apr 2025
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates
08:05pm, Thursday, 27'th Mar 2025
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript
06:44pm, Thursday, 27'th Mar 2025
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
04:01pm, Thursday, 27'th Mar 2025
SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
09:30am, Thursday, 13'th Mar 2025
SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
03:30pm, Thursday, 06'th Mar 2025
SALT LAKE CITY , March 6, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development o
